HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) had its target price lifted by equities research analysts at HC Wainwright from $13.00 to $17.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 345.03% from the company's previous close.

Separately, Piper Sandler upped their target price on Cardiff Oncology from $7.00 to $10.00 and gave the company an "overweight" rating in a report on Friday, December 13th.

Cardiff Oncology Stock Down 9.9 %

Shares of NASDAQ:CRDF traded down $0.42 during trading on Friday, hitting $3.82. 1,273,865 shares of the company traded hands, compared to its average volume of 1,177,802. The stock has a market capitalization of $195.33 million, a price-to-earnings ratio of -4.06 and a beta of 1.77. The business's fifty day moving average is $4.06 and its 200-day moving average is $3.25. Cardiff Oncology has a one year low of $2.01 and a one year high of $6.42.

Insider Buying and Selling

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average cost of $2.60 per share, with a total value of $910,299.00. Following the acquisition, the director now directly owns 1,047,876 shares of the company's stock, valued at $2,724,477.60. This represents a 50.18 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.80% of the company's stock.

Hedge Funds Weigh In On Cardiff Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new position in Cardiff Oncology in the 4th quarter worth approximately $25,000. ProShare Advisors LLC bought a new position in Cardiff Oncology during the 4th quarter valued at $50,000. Raymond James Financial Inc. bought a new position in Cardiff Oncology during the 4th quarter valued at $56,000. Voya Investment Management LLC bought a new position in Cardiff Oncology during the 4th quarter valued at $57,000. Finally, Caxton Corp bought a new position in Cardiff Oncology during the 4th quarter valued at $58,000. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.